Tinterri Corrado, Sagona Andrea, Barbieri Erika, Di Maria Grimaldi Simone, Jacobs Flavia, Zambelli Alberto, Trimboli Rubina Manuela, Bernardi Daniela, Vinci Valeriano, Gentile Damiano
Breast Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy.
Cancers (Basel). 2022 Dec 17;14(24):6237. doi: 10.3390/cancers14246237.
Loco-regional therapy (LRT) in de novo metastatic breast cancer (MBC) has been investigated in several clinical trials, with heterogeneous and conflicting results.
We conducted a retrospective study of de novo MBC patients treated with front-line chemotherapy (FLC) followed by LRT of the primary tumor. Our aims were to evaluate the characteristics, treatment, and oncological outcomes in terms of progression-free survival (PFS), distant progression-free survival (DPFS), and overall survival (OS) of de novo MBC. We also investigated possible subgroups of patients with better outcomes according to menopausal status, biological sub-type, location, number of metastases, and radiologic complete response after FLC.
We included 61 patients in the study. After a median follow-up of 55 months, disease progression occurred in 60.7% of patients and 49.2% died. There were no significant differences in PFS, DPFS, and OS between different subgroups of de novo MBC patients. A trend toward better PFS and DPFS was observed in triple-positive tumors, without a statistically significant difference in OS.
No specific subgroup of de novo MBC patients showed a statistically significant survival advantage after FLC followed by LRT of the primary tumor.
在多项临床试验中对初诊转移性乳腺癌（MBC）的局部区域治疗（LRT）进行了研究，结果各异且相互矛盾。
我们对接受一线化疗（FLC）后行原发肿瘤LRT的初诊MBC患者进行了一项回顾性研究。我们的目的是根据初诊MBC的无进展生存期（PFS）、远处无进展生存期（DPFS）和总生存期（OS）评估其特征、治疗及肿瘤学结局。我们还根据绝经状态、生物学亚型、部位、转移灶数量以及FLC后的放射学完全缓解情况，研究了可能预后较好的患者亚组。
我们纳入了61例患者进行研究。中位随访55个月后，60.7%的患者出现疾病进展，49.2%的患者死亡。初诊MBC患者的不同亚组之间，PFS、DPFS和OS无显著差异。三阳性肿瘤患者的PFS和DPFS有改善趋势，但OS无统计学显著差异。
在接受FLC后行原发肿瘤LRT的初诊MBC患者中，没有特定亚组显示出统计学显著的生存优势。
Zotero 插件
